Washington University School of Medicine, St Louis, MI, USA.
Crit Care Resusc. 2009 Dec;11(4):282-6.
In bacterial and fungal infections, optimal outcomes are obtained through the timely provision of adequate antimicrobial coverage in an initial anti-infective treatment regimen. However, selecting appropriate antimicrobial regimens to treat infections in the intensive care unit is challenging because of the expansion of antibiotic resistance. Multidrug anti-infective regimens are typically needed to adequately cover common important pathogens in ICUs. Here, we describe novel antibacterial agents in the late stages of clinical development that show potential for treating methicillin-resistant Staphylococcus aureus (MRSA) infections. These include the fifth-generation cephalosporins, ceftaroline and ceftobiprole; the glycopeptides, dalbavancin, oritavancin, and telavancin; and iclaprim.
在细菌和真菌感染中，通过在初始抗感染治疗方案中及时提供充分的抗菌覆盖，可以获得最佳疗效。然而，由于抗生素耐药性的不断扩大，选择适当的抗感染治疗方案来治疗重症监护病房（ICU）的感染具有挑战性。通常需要多药抗感染方案来充分覆盖 ICU 中常见的重要病原体。在这里，我们描述了处于临床开发后期的新型抗菌药物，这些药物具有治疗耐甲氧西林金黄色葡萄球菌（MRSA）感染的潜力。这些药物包括第五代头孢菌素头孢洛林和头孢托罗匹酯、糖肽类药物达巴万星、奥他万星和替拉万星，以及伊克拉普林。
